The FDA has approved Abilify (aripiprazole, from Bristol-Myers Squibb and Otsuka) for the maintenance treatment of manic and mixed episodes associated with bipolar I disorder, with or without psychotic features, in children 10-17 years of age and for the maintenance treatment of schizophrenia in adolescents 13-17 years of age.

Abilify also gained an indication as an adjunctive therapy to either lithium or valproate for the acute treatment of adults and children ≥10 years of age with manic and mixed episodes associated with bipolar I disorder with or without psychotic features. When used as monotherapy for bipolar I disorder in adults, Abilify now has a lower recommended starting and target dose.

For more information call (800) 321-1335 or visit www.abilify.com.